$1.86
0.042.2%
Last update: Aug 21, 9:26 AM
Karyopharm Therapeutics Inc
KPTINASDAQ
Karyopharm Therapeutics Earnings & Forecasts
Karyopharm Therapeutics (KPTI) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Karyopharm Therapeutics Guidance
Karyopharm Therapeutics (KPTI) last issued guidance on August 13, 2026 for fiscal year 2026. The company guided revenue in the range of $130M - $150M for the period.
Compared to prior guidance, Karyopharm Therapeutics maintained its revenue forecast from a prior range of $130M - $150M.
Karyopharm Therapeutics has issued 24 guidance updates between November 3, 2022 and August 13, 2026. During this period, the company raised its outlook 5 times and lowered it 10 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-1.42 | $-1.44 | $-2.10 | $-3.27 |
| Actual | $-2.32 | $-1.24 | $-2.23 | $-3.82 |
| Surprise | -63.4% | +13.9% | -6.19% | -16.8% |
| Revenue | ||||
| Estimate | $32.1M | $31.9M | $33.2M | $42.4M |
| Actual | $33.4M | $35.1M | $34.1M | $44.0M |
| Surprise | +4.21% | +9.91% | +2.77% | +3.86% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.28 | $-1.18 | $-1.14 | $-1.01 |
| Revenue | ||||
| Consensus | $33.4M | $34.3M | — | — |
